StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) income statement

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.03−0.03 (-2.83%)

Close on Nov 18, 2026Market cap $103.35MP/E –Yield –

Cellectis S.A. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
100.0%
Operating margin
-45.3%
Net margin
-92.7%
Return on equity, FY2025
-65.3%

Financial strength

Current ratio
–
Debt to equity
–
Debt to assets
–
Cash to current liabilities
26.4%

Valuation

P/E ratio
–
Price to sales
1.42
Price to book
2.52
Dividend yield
–

See a number that looks wrong?